• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » How Effective Are the Newest Antipsychotics?
CLINICAL UPDATE

How Effective Are the Newest Antipsychotics?

February 1, 2012
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Caroline Fisher, PhD, MD

Four new antipsychotics are beginning to gain some traction in the adult market. To be absolutely clear, among these only paliperidone (Invega) has been approved for use in children and adolescents (those age 12 and older). None of the other medications have been tested in this age group. But for those of us who see transitional age youth to whom we prescribe antipsychotics, here is a quick low down on paliperidone, iloperidone (Fanapt), lurasidone (Latuda), and asenapine (Saphris).

Paliperidone (Invega) is the oldest of the set, and is the active metabolite of risperidone (Risperdal). It has been touted as having fewer side effects than risperidone, but it seems to have outlived its honeymoon period: the literature abounds with case reports of the usual trouble-makers (weight gain, sedation, hyperprolactinemia) and serious side effects (dystonia, tardive dyskinesia, neuroleptic malignant syndrome). Thus, it appears to have much the same effect—both for better and for worse—as risperidone. The good news is that any patient who has been on risperidone in the past has already been exposed to paliperidone, so it’s reasonably safe (as safe as risperidone), though much more expensive than its mother compound

Table 1: Invega At-a-Glance

Click here to open pdf


Iloperidone (Fanapt) is FDA-approved for the treatment of schizophrenia in adults. There are four studies available on this drug: three short-term studies demonstrating comparable effect to haloperidol (Haldol) in treating acute psychosis in adults with schizophrenia, and one continuation study lasting 46 weeks (after a six week acute study) measuring side effects and time to relapse. The news is disappointing for relapse: while it was found “non-inferior” to haloperidol, median time to relapse was 50 days on iloperidone and 78 days on haloperidol; not statistically different. Further, iloperidone causes significant weight gain—in this study, 10.6 lbs as compared to haloperidol’s average 6.6 lbs. A disconcerting fact is that six people in the iloperidone group died—though only one of these deaths was attributed to the medication (Kane JM et al, J Clin Psychopharmacol 2008;28(2):S29–S35). Cognitive measures were not studied, but some hypothesize that it will improve cognition via serotonergic action, particularly at 5-HT7 receptors (Kane JM ibid).


Table 2: Fanapt At-a-Glance

Click here to open pdf


Lurasidone (Latuda) is FDA-approved to treat schizophrenia in adults. It works at 80 mg daily, and perhaps at 40 mg daily, with no increased benefit at doses higher than 80 mg daily. Time to onset of effect is three to seven days. The encouraging news is that it does not seem to make people fat or increase lipids or glucose, nor does it increase prolactin or cause QTC prolongation (L Citrome, Int J Clin Pract 2011;65(2):189–210). Studies of rats suggest it could cause cognitive enhancement, but the one study looking at cognitive measures in humans after treatment with lurasidone failed to clearly differentiate from ziprasidone (Geodon), and from the practice effect (Harvey PD, Schiz Res 2011;127:188–194). The study may not have been sufficiently powered, however. The down side of lurasidone is that it caused akathisia in 22% of study patients, with a number needed to harm of six.


Table 3: Latuda At-a-Glance

Click here to open pdf


Asenapine (Saphris) is FDA-approved for both schizophrenia and bipolar disorder in adults, at 5 mg twice a day and 10 mg twice daily respectively. It has the disadvantage of requiring sublingual administration, since its bioavailability is less than 2% if swallowed. Patients say the pill leaves a bad taste under the tongue, but there is now a black currant flavor that is a little better. Suggest to your patients that they chew a strong-flavored mint or gum before taking it, or suck on an ice cube. Patients must avoid any food or drink for 10 minutes after taking a dose. Furthermore, any meal eaten up to four hours after ingestion reduces the bioavailability by approximately 20%.

Asenapine causes some drug interaction mischief. It is metabolized by CYP 1A2, and so is subject to CYP1A2 inhibitors like fluvoxamine (Luvox). In addition, it inhibits CYP2D6, and can thus increase the serum levels of drugs metabolized by that system, such as paroxetine (Paxil).

Like lurasidone, asenapine seems to cause fewer metabolic problems than other atypicals. On the downside, it frequently causes sedation and akathisia (but less EPS than haloperidol), and infrequent elevations in prolactin. It also causes oral numbing in 4% of patients. Weight gain is primarily a problem in relatively skinny patients (BMI less than 23). Mild QTC prolongation occurs, but a more frequent cardiac side effect is reflex bradycardia (slow heart rate) with sinus pause. Although benign and self-limiting, this could easily frighten a patient. Efficacy studies were sufficient for FDA approval, but overall are unimpressive, with no increased efficacy over comparator drugs, and some studies failed to find a difference from placebo (Citrome L, Int J Clin Pract 2009;63(12):1762–1784).

Table 4: Saphris At-a-Glance

Click here to open pdf


Child Psychiatry Clinical Update
KEYWORDS child-psychiatry free_articles personality disorders
    www.thecarlatreport.com
    Issue Date: February 1, 2012
    SUBSCRIBE NOW
    Table Of Contents
    What You Need to Know About Callous-Unemotional Traits and Disruptive Behavioral Disorders
    How Effective Are the Newest Antipsychotics?
    Treating Violent and Antisocial Children and Adolescents
    DOWNLOAD NOW
    Featured Book
    • PB4e_Cover2.png

      Psychiatry Practice Boosters, Fourth Edition (2023)

      Teaches you the key points of 63 of the most clinically relevant studies in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2432683359.jpg
      Child Psychiatry

      Hidden Dangers: The Fentanyl Crisis and Teen Overdose Prevention

      The Fentanyl overdose crisis is now one of the leading causes of death among adolescents, and it is happening in every corner of the country. Stay with us as we talk about the...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.